Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPAC-IOV phase II study of pressurized intraperitoneal aerosol chemotherapy in peritoneal carcinomatosis
2020-000560-37Phase 2Completed
- Sponsor
- Istituto Oncologico Veneto
- Start
- Oct 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin, cisplatin and oxaliplatin in peritoneal carcinomatosis (PC), sponsored by Istituto Oncologico Veneto. Primary endpoint: Histological response by PRGS. Started Oct 2020; status: completed.
02
Drugs
doxorubicincisplatinoxaliplatin
03
Conditions
peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on 2020-000560-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000560-37.